{"preliminary_commentary":{"by_channel":{"x_thread":9,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04248829\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"LASER301","nct_id":"NCT04248829","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=laser301-nct04248829. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Lazertinib (240 mg or 160 mg orally, once daily) plus Gefitinib-matching placebo (250 mg orally, once daily) in accordance with the randomization schedule","label":"Lazertinib + Gefitinib-matching placebo","type":"EXPERIMENTAL"},{"description":"Gefitinib (250 mg orally, once daily) plus Lazertinib-matching placebo (240 mg or 160 mg orally, once daily) in accordance with the randomization schedule","label":"Gefitinib + Lazertinib-matching placebo","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-04-22","type":"ACTUAL"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":393,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Lazertinib 240 mg/160 mg","otherNames":["YH25448 240 mg/160 mg"],"type":"DRUG"},{"name":"Gefitinib 250 mg","otherNames":["Iressa 250 mg"],"type":"DRUG"},{"name":"Lazertinib-matching placebo 240 mg/160 mg","otherNames":["YH25448-matching placebo 240 mg/160 mg"],"type":"DRUG"},{"name":"Gefitinib-matching placebo 250 mg","otherNames":["Iressa-matching placebo 250 mg"],"type":"DRUG"}],"last_update":"2026-06-29","lead_sponsor":"Yuhan Corporation","official_title":"A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-07-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment","timeFrame":"At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant."}],"references":[{"citation":"Soo RA, Cho BC, Kim JH, Ahn MJ, Lee KH, Zimina A, Orlov S, Bondarenko I, Lee YG, Lim YN, Lee SS, Lee KH, Pang YK, Fong CH, Kang JH, Lim CS, Danchaivijitr P, Kilickap S, Yang JC, Arslan C, Lee H, Park SN, Cicin I. Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis. J Thorac Oncol. 2023 Dec;18(12):1756-1766. doi: 10.1016/j.jtho.2023.08.017. Epub 2023 Oct 22.","pmid":"37865896","type":"DERIVED"},{"citation":"Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301. J Clin Oncol. 2023 Sep 10;41(26):4208-4217. doi: 10.1200/JCO.23.00515. Epub 2023 Jun 28.","pmid":"37379502","type":"DERIVED"}],"start_date":{"date":"2020-02-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)","url":"https://clinicaltrials.gov/study/NCT04248829"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/laser301-nct04248829"}